Cancer patients are benefiting from Iressa's expanded access program

Published: 2003-04-15 06:58:00

Updated: 2003-04-15 06:58:00

The Korea Food and Drug Administration said it will continue to conduct an expanded access program of Iressa treatment for patients with a non-small cell lung cancer who no longer respond to conventional chemotherapy, as a longer period for formal market authorization and assessment of insurance ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK